Chronic urticaria (CU) is highly variable in severity and clinical type, so treatment regimens should be individualized. As with other allergic diseases, treatment should include avoidance of triggers if specific triggers are identified. The common drugs used clinically to treat urticaria are antihistamines. First-generation antihistamines (e.g., paracetamol, cytisine, etc.) are effective in reducing symptoms and the number of lesions, but often have side effects such as sedation (drowsiness) and anticholinergics, limiting their long-term and daytime use. Second-generation antihistamines (e.g., loratadine) are weakly sedating and are currently the first-line drugs used in clinical treatment. It is generally recommended to be taken continuously and regularly for 3-6 months, followed by gradual dose reduction. For one drug alone cannot effectively control symptoms this, options such as doubling the dose and combining with other different types of antihistamines can be considered. Some studies have confirmed that the combination of H1-blockers and H2-blockers is more effective in treating CU than H1-blockers alone. However, there are also studies that have not confirmed this effect. Some of the effective patients may be associated with increased blood levels of H1 receptor antagonists as a result of H2 receptor blockade, so this treatment option warrants further investigation. Hormones may be considered in those who do not respond to antihistamines (combination and high dose). There are no large double-blind placebo-controlled studies looking at the efficacy and safety of long-term hormone use in chronic urticaria. Because of possible side effects, hormone use is generally limited to patients with acute urticaria and acute episodes of chronic urticaria. The standard starting dose is 0.5-1.0 mg/kg/d, followed by a gradual reduction to a dose that maintains the effect. As the duration of treatment increases, the chance of hormone-induced side effects increases, so risks and benefits should be carefully considered. The therapeutic value of thyroxine in CU remains undetermined. Intravenous gamma globulin, plasma replacement, and environmental protection bacteriocins have been shown to be effective in urticaria in selected studies. These treatments may be considered in severe urticaria, especially autoimmune, that does not respond to drug therapy. Colchicine and aminophenazone have been reported to be effective in intractable urticaria and urticarial vasculitis. Anti-IgE antibodies and anti-leukotriene agents have been reported to be effective in some cases, but there is a lack of large-scale clinical studies, so their role remains controversial.